Evidence map›Paper›PMID 28396778›Full record

ArticleClinical case reports2017

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.

Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Ilaria Migliaccio, Dalila Salvatore, Marco Picardi, Fabrizio Pane, Lucio Catalano

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudio CerchioneHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Davide NappiHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Maria Di PernaHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Irene ZacheoHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Ilaria MigliaccioHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Dalila SalvatoreHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Marco PicardiHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Fabrizio PaneHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.
Lucio CatalanoHematology Azienda Ospedaliera Universitaria Federico II Via Pansini 5 Naples 80131 Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without "a priori" exclusion of ancient drugs, even after failure of the ultimate pharmacological options.

Indexed as

Bendamustineheavily pretreatedmultiple myelomapomalidomiderefractoryrelapsed

Identifiers

PMID28396778
PMCPMC5378832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.